Anieta M Sieuwerts

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 15:101-11. 2008
  2. pmc Genome-wide DNA methylation profiling of non-small cell lung carcinomas
    Rejane Hughes Carvalho
    Department of Cell Biology, ErasmusMC, PO Box 2040, Rotterdam, CA, 3000, The Netherlands
    Epigenetics Chromatin 5:9. 2012
  3. pmc Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
    Jérôme Toussaint
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 10:424. 2009
  4. pmc Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
    Jack X Yu
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    BMC Cancer 7:182. 2007
  5. ncbi Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Chem 53:1280-8. 2007
  6. pmc Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:61-6. 2009
  7. doi Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus MC, Room BE 400, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Breast Cancer Res Treat 118:455-68. 2009
  8. ncbi How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 11:7311-21. 2005
  9. pmc Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, GE, The Netherlands
    Breast Cancer Res 12:R103. 2010
  10. ncbi Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Clin Cancer Res 12:3319-28. 2006

Collaborators

Detail Information

Publications47

  1. ncbi Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 15:101-11. 2008
    ..In addition, as altered expression of FGF17 causes tamoxifen resistance in vitro, the FGF signaling pathway could be a valuable target in the treatment of breast cancer patients resistant to endocrine treatment...
  2. pmc Genome-wide DNA methylation profiling of non-small cell lung carcinomas
    Rejane Hughes Carvalho
    Department of Cell Biology, ErasmusMC, PO Box 2040, Rotterdam, CA, 3000, The Netherlands
    Epigenetics Chromatin 5:9. 2012
    ..abstract:..
  3. pmc Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
    Jérôme Toussaint
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 10:424. 2009
    ....
  4. pmc Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
    Jack X Yu
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    BMC Cancer 7:182. 2007
    ..Published prognostic gene signatures in breast cancer have few genes in common. Here we provide a rationale for this observation by studying the prognostic power and the underlying biological pathways of different gene signatures...
  5. ncbi Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Chem 53:1280-8. 2007
    ..TIMP-1 protein is a prognostic factor for recurrence-free and overall survival (OS) time in breast cancer. We evaluated the prognostic value of TIMP1 mRNA and a novel TIMP1 mRNA splice variant in 1301 primary breast cancer patients...
  6. pmc Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:61-6. 2009
    ..New tests that include antibodies that specifically recognize normal-like breast tumor cells but not cells of hematopoietic origin are needed...
  7. doi Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus MC, Room BE 400, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Breast Cancer Res Treat 118:455-68. 2009
    ..Our method allows molecular characterization specific for as little as one CTC, and can be used to expand the understanding of the biology of metastasis and, potentially, to improve patient management...
  8. ncbi How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 11:7311-21. 2005
    ..To evaluate the predictive value of the disintegrin and metalloproteinases, ADAM-9, ADAM-10, ADAM-11, and ADAM-12, and of the matrix metalloproteinases, MMP-2 and MMP-9, in patients with recurrent breast cancer treated with tamoxifen...
  9. pmc Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, GE, The Netherlands
    Breast Cancer Res 12:R103. 2010
    ....
  10. ncbi Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Clin Cancer Res 12:3319-28. 2006
    ..To evaluate the prognostic value of cyclin E with a quantitative method for lymph node-negative primary breast cancer patients...
  11. doi TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Room Be 432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 113:253-60. 2009
    ..Both TSC22D1 and PSAP are associated with clinical outcome and may have a functional role in therapy resistance...
  12. doi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
    ..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance...
  13. doi Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance
    Ton van Agthoven
    Department of Pathology, Cancer Genomics Center, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 27:542-9. 2009
    ..Here, we explored whether these BCAR genes provide predictive value for tamoxifen resistance and prognostic information for tumor aggressiveness in breast cancer patients...
  14. doi MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
    F Germán Rodríguez-González
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, Be 4 02 lab 4 35b office, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 127:43-51. 2011
    ..Assessment of tumor levels and connected pathways could be helpful to improve treatment strategies...
  15. doi Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response
    Ton van Agthoven
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Be432, Erasmus MC PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Endocr Relat Cancer 17:215-30. 2010
    ....
  16. ncbi HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
    ..However, this ratio may predict a tumor's response to tamoxifen, its intrinsic aggressiveness, or both...
  17. ncbi Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer
    John W M Martens
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 65:4101-17. 2005
    ..Concluding, our work indicates that promoter hypermethylation and mRNA expression of PSAT1 are indicators of response to tamoxifen-based endocrine therapy in steroid hormone receptor-positive patients with recurrent breast cancer...
  18. ncbi Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 122:125-33. 2010
    ..Together, our observations suggest that alpha-catenin may be a new tumor suppressor gene that operates in the E-cadherin tumor suppressor pathway...
  19. doi mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Rotterdam, The Netherlands
    Clin Cancer Res 17:3600-18. 2011
    ..In this study, we determined mRNA and microRNA (miRNA) expression of potentially CTC-specific genes that are considered to be clinically relevant in breast cancer...
  20. doi Subtypes of breast cancer show preferential site of relapse
    Marcel Smid
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Res 68:3108-14. 2008
    ..The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site...
  21. doi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
    ....
  22. pmc Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands
    Proc Natl Acad Sci U S A 105:13021-6. 2008
    ..In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein...
  23. doi Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes
    Muhammad Riaz
    Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus MC, Building Be, Room 400, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Breast Cancer Res Treat 133:843-51. 2012
    ..Also the prognosis of patients is largely not affected by low-risk breast cancer loci except for the SNP near H19. How, this SNP affects prognosis warrants further study as it does not operate through altering H19 mRNA expression...
  24. ncbi Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1
    Buddy Setyono-Han
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, 3000 DR Rotterdam, The Netherlands
    Thromb Haemost 93:779-86. 2005
    ..In conclusion, our results provide evidence that WX-UK1 as a single agent inhibits breast tumour growth and metastasis in vivo, and thus is a promising candidate drug to treat human cancer...
  25. ncbi Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression
    John W M Martens
    Dept of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Thromb Haemost 89:393-404. 2003
    ..These age-induced levels of PAI-1, FGF-1, uPA and MMP-2 in stromal breast fibroblast could contribute to breast cancer progression...
  26. doi KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue
    Bianca Mostert
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Int J Cancer 133:130-41. 2013
    ..Determination of KRAS and BRAF mutations in CTCs is challenging but feasible. Of the tested methods, nested ASB-PCR, enabling detection of KRAS and BRAF mutations in patients with as little as two CTCs, seems to be superior...
  27. doi CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes
    Bianca Mostert
    Erasmus MC, Department of Medical Oncology, Daniel den Hoed Cancer Center and Laboratory of Translational Tumor Immunology, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Cancer Lett 319:49-55. 2012
    ..Combined staining of CK8/18/19 and CD49f after CD146/EpCAM enrichment is likely to further improve CTC detection in breast cancer...
  28. ncbi Genes associated with breast cancer metastatic to bone
    Marcel Smid
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
    J Clin Oncol 24:2261-7. 2006
    ..The biology of tumors relapsing to bone is poorly understood. In this study, we initiated a search for genes that are implicated in tumors relapsing to bone in breast cancer...
  29. pmc Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer
    Ning Qing Liu
    Affiliations of authors Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands NQL, MPL, MS, RBHB, TDM, AMS, JWMM, JAF, AU Department of Neurology CS, TML and Postgraduate School of Molecular Medicine NQL, RBHB, TDM, AMS, JWMM, JAF, AU, Erasmus University Medical Center, Rotterdam, The Netherlands Department of Radiation Oncology PNS and Department of Laboratory Medicine FCGJS, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden BKL Department of Oncology Pathology, Karolinska Institute, Stockholm, Sweden BKL Clinical Experimental Oncology Laboratory, National Cancer Centre Giovanni Paolo II, Bari, Italy AM, AP Translational Cancer Research Unit, Oncology Center, GZA Hospitals St Augustinus
    J Natl Cancer Inst 106:djt376. 2014
    ..Clinical outcome of patients with triple-negative breast cancer (TNBC) is highly variable. This study aims to identify and validate a prognostic protein signature for TNBC patients to reduce unnecessary adjuvant systemic therapy...
  30. doi Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Breast Cancer Res Treat 138:47-57. 2013
    ..The discrepancy between E-cadherin loss and EMT was thus reproduced in clinical samples. Together, these results indicate that in human breast cancer loss of E-cadherin is not causal for EMT and even not a necessity...
  31. doi Hormone replacement therapy dependent changes in breast cancer-related gene expression in breast tissue of healthy postmenopausal women
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, Netherlands
    Mol Oncol 5:504-16. 2011
    ..This feasibility study provides the basis for whole genome analyses to identify novel markers involved in increased breast cancer risk...
  32. doi Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146
    Bianca Mostert
    Department of Medical Oncology, Daniel den Hoed Cancer Center and Laboratory of Translational Tumor Immunology, Erasmus MC, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Breast Cancer Res Treat 127:33-41. 2011
    ..CD146+ CTCs are present in the peripheral blood of breast cancer patients with advanced disease. Combined use of anti-CD146 and anti-EpCAM is likely to improve CTC detection in breast cancer patients...
  33. ncbi Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005
    ..To discover a set of markers predictive for the type of response to endocrine therapy with the antiestrogen tamoxifen using gene expression profiling...
  34. doi Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes
    Jord H A Nagel
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Breast Cancer Res Treat 132:439-48. 2012
    ..Identification of these as-yet-unknown susceptibility alleles should be aided by clues from the 40-gene CHEK2 signature...
  35. ncbi Circulating tumour cell detection on its way to routine diagnostic implementation?
    Stefan Sleijfer
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Clinic, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 43:2645-50. 2007
    ..This review addresses CTCs, and in particular, technical issues concerning their detection, clinical results obtained so far, and future perspectives...
  36. doi Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes
    Marcel Smid
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus MC, Dr, Rotterdam, The Netherlands
    Breast Cancer Res Treat 128:23-30. 2011
    ..In contrast, CIN is clearly associated with progression in ER-positive, luminal B, and her2/neu subtypes; thus, assessing CIN in these subtypes may contribute to personalized patient management...
  37. ncbi Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 24:1665-71. 2006
    ..The aim of this study was to validate this gene signature in an independent more diverse population of LNN patients from multiple institutions...
  38. doi The challenge of gene expression profiling in heterogeneous clinical samples
    F Germán Rodríguez-González
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus Medical Center, Rotterdam, The Netherlands
    Methods 59:47-58. 2013
    ....
  39. pmc High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes
    Muhammad Riaz
    Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology and Cancer Genomics Center, Rotterdam, The Netherlands
    Breast Cancer Res 14:R123. 2012
    ..The biological associations suggest an involvement of the tumor microenvironment in TWIST1's adverse role in breast cancer...
  40. doi Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients
    Bianca Mostert
    Daniel den Hoed Cancer Center, Laboratory of Clinical Tumor Immunology, Rotterdam, The Netherlands
    Expert Rev Mol Diagn 11:259-75. 2011
    ....
  41. ncbi Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts
    Anieta M Sieuwerts
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Thromb Haemost 87:674-83. 2002
    ....
  42. pmc Differential expression of splicing variants of the human caldesmon gene (CALD1) in glioma neovascularization versus normal brain microvasculature
    Ping Pin Zheng
    Department of Pathology, Internal Oncology, Neuro Oncology and Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    Am J Pathol 164:2217-28. 2004
    ..The event coexists with tight junction (TJ) breakdown of the endothelial cells in glioma microvasculature. The data reveal a novel mechanism contributing to dysfunctionality of glioma neovascularization...
  43. doi Multiplex molecular analysis of CTCs
    Anieta M Sieuwerts
    Department of Translational Cancer Genomics and Proteomics, Erasmus Medical Center, Rotterdam, The Netherlands
    Recent Results Cancer Res 195:125-40. 2012
    ..However, most of what is discussed will apply to any multiplex analysis of CTCs, irrespective of the enrichment method...
  44. ncbi Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor
    Matthias Kotzsch
    Institute of Pathology, Dresden University of Technology, Fetscherstr 74, 01307, Dresden, Germany
    Breast Cancer Res Treat 111:229-40. 2008
    ..To evaluate the pure prognostic impact of the uPA-receptor splice variant uPAR-del4/5 for lymph node-negative breast cancer patients, and to identify differentially expressed genes associated with high or low uPAR-del4/5 mRNA levels...
  45. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  46. ncbi DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients
    Inko Nimmrich
    Department of Biomedical Research and Development and Technology Development, Epigenomics AG, Berlin, Germany
    Breast Cancer Res Treat 111:429-37. 2008
    ..In addition, we studied the association between PITX2 DNA methylation and PITX2 gene expression...
  47. ncbi Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer
    Selina Raguz
    Medical Research Council Clinical Sciences Centre, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, London, United Kingdom
    Int J Cancer 122:1058-67. 2008
    ....